ERBB2 and breast carcinoma: We also found RB1 mutations to be significantly depleted in B7-H3–high breast cancers that are hormone receptor (estrogen receptor/progesterone receptor) positive (HR+)/HER2 negative (1.6% vs. 8.7%, q < 0.0001).